KRAS and colorectal carcinoma: PCSK9 inhibitors exerted significant inhibitory effects in human APC/KRAS-mutant CRC primary organoids (Fig. 5I), and inhibited cholesterol biosynthesis pathway, as determined by qPCR and western blot (Fig. 5J).